Fennec Pharmaceuticals (TSX:FRX) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


TSX:FRX Fennec Pharmaceuticals Inc TSX:FRX
54 GF Score
Price C$14.74
GF Value C$14.13
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Fennec Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

TSX:FRX vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Fennec Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fennec Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


TSX:FRX
54GF Score
Fennec Pharmaceuticals Inc TSX:FRX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fennec Pharmaceuticals (TSX:FRX) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of C$14.74 is trading 4.3% above its estimated GF Value™ of C$14.13. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for TSX:FRX:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: C$14.13 vs. price of C$14.74 (4.3% above fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the TSX:FRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fennec Pharmaceuticals Business Description

Other Exchanges FENC:USARV41:Germany
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
54GF Score

Get the complete analysis for TSX:FRX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$14.74
Price
C$14.13
GF Value